Additionally, our findings revealed that EZH2 inhibition modulates the negative ferroptosis markers SLC7A11, NFS1, and FSP1. Collectively, our study illuminates distinct transcriptional changes triggered by EZH2 inhibition, suggesting a pivotal role in promoting lipid ROS accumulation, potentially leading to ferroptotic cell death in HCC. This evidence concerns the gene EZH2 and hepatocellular carcinoma.